Study Evaluating the Effect of Lecozotan SR on the QTc Interval

Wyeth

Status and phase: Completed; Phase 1

Conditions: Healthy; Alzheimer Disease

Treatments: Drug: Moxifloxacin; Drug: Lecozotan SR

Study type: Interventional

Funder types: Industry

Identifiers

NCT00499642

3098B1-133

Details and patient eligibility

About

This is a randomized, double-blind, placebo- and moxifloxacin (open-label)-controlled, 4-period crossover study.

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Women and men aged 18 to 55 years inclusive.
• Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG).

Exclusion criteria

• History of any clinically important drug allergy.
• Positive findings of urine drug screen (eg, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind